Asthma: Anti-Immunoglobulin E Therapy with Omalizumab for Asthma

Abstract

Spanish

French

Objective:

To evaluate data on anti-immunoglobulin E (anti-IgE) therapy for asthma.

Data Sources:

Information was selected from PubMed from 1989 to May 2007 using the search term omalizumab and included randomized, controlled trials. These studies evaluated asthma treatment with omalizumab and focused on its efficacy, tolerability, and cost-effectiveness in this population.

Study Selection and Data Extraction:

All randomized clinical trials were reviewed (23 were identified and 19 were included; 3 were not relevant and 1 contained duplicative data). Other articles using the search words anti-IgE therapy and cost-effectiveness were evaluated; relevant information was extracted.

Data Synthesis:

IgE-dependent mechanisms play an important role in the development and maintenance of airway inflammation in asthma. Omalizumab is a subcutaneously administered monoclonal anti-IgE antibody that reduces unbound IgE concentrations and promotes down-regulation of IgE receptors. Results from clinical trials in adults, adolescents, and children with poorly controlled IgE-mediated asthma have shown that omalizumab improves symptom control and allows patients to be managed with lower doses of inhaled corticosteroids (ICS). It has been well tolerated in clinical trials lasting as long as 52 weeks, but injection-site reactions are common (45% in omalizumab group vs 43% in placebo group) and anaphylaxis has occurred in 0.2% of patients. A consensus expert panel has recommended that omalizumab should be considered for patients 12 years of age or older with allergic asthma who are inadequately controlled on guideline-based therapy and require maintenance therapy with systemic corticosteroids or high-dose ICSs, or who have poor adherence to ICS therapy.

Conclusions:

Anti-IgE therapy provides an effective and generally safe approach to the treatment of patients with IgE-mediated asthma who are not adequately controlled by conventional guideline-based medications. However, the potential benefit must be weighed against the cost and inconvenience of this new therapy.

Keywords

asthma immunoglobulin E monoclonal antibody

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention (CDC). Environmental hazards and health effects program. Asthma. Program in brief. www.cdc.gov/asthma/program.htm (accessed 2006 Oct 26).

American Lung Association. Lung disease data: 2006. www.lungusa.org/atf/cf/{7A8D42C2-FCCA-4604-8ADE-7F5D5E762256}/LDD2006 (accessed 2007 Feb 20).

Chung

. Unmet needs in adult asthma. Clin Exp Allergy 2000;30(suppl 1): 66–9.

National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Clinical practice guidelines: expert panel report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program; 1997. NIH publication 97–4051.

Dolan

Fraher

Bleecker

. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32–9.

Bateman

Boushey

Bousquet

. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–44.

Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention. Medical Communications Resources, Inc., 2006. www.ginasthma.com/Guidelineitem.asp??11=2&12=1&intID=37 (accessed 2007 Aug 3).

National Asthma Education and Prevention Program. Full report of the Expert Panel: guidelines for the diagnosis and management of asthma (EPR-3). Washington, DC: National Heart, Lung, and Blood Institute, DRAFT January 2007.

Presta

Lahr

Shields

. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623–32.

10.

MacGlashan

Jr.

McKenzie-White

Chichester

. In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 1998;91:1633–43.

11.

Huang

Leyko

Frieri

. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol 2005;95:443–51.

12.

Lin

Boesel

Griffith

. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113:297–302.

13.

Beck

Marcotte

MacGlashan

Togias

Saini

. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol 2004;114:527–30.

14.

Prussin

Griffith

Boesel

Lin

Foster

Casale

. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147–54.

15.

Djukanovic

Wilson

Kraft

. Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583–93.

16.

Prieto

Gutierrez

Colas

. Effect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 2006;139:122–31.

17.

Noga

Hanf

Brachmann

. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:1493–9.

18.

Package insert. Xolair (omalizumab). San Francisco, CA: Genentech, Inc., June 2003.

19.

Hochhaus

Brookman

Fox

. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491–8.

20.

Soler

Matz

Townley

. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254–61.

21.

Busse

Corren

Lanier

. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–90.

22.

Buhl

Soler

Matz

. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73–8.

23.

Lanier

Corren

Lumry

Liu

Fowler-Taylor

Gupta

. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154–9.

24.

Humbert

Beasley

Ayres

. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–16.

25.

Ayres

Higgins

Chilvers

Ayre

Blogg

Fox

. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701–8.

26.

Milgrom

Berger

Nayak

. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108: e36(1–10).

27.

Holgate

Bousquet

Wenzel

Fox

Liu

Castellsague

. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17:233–40.

28.

Corren

Casale

Deniz

Ashby

. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87–90.

29.

Niebauer

Dewilde

Fox-Rushby

Revicki

. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol 2006;96:316–26.

30.

Buhl

Hanf

Soler

. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088–94.

31.

Finn

Gross

van Bavel

. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278–84.

32.

Holgate

Chuchalin

Hebert

. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632–8.

33.

Lemanske

Jr.

Nayak

McAlary

Everhard

Fowler-Taylor

Gupta

. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110: e55.

34.

Vignola

Humbert

Bousquet

. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709–17.

35.

Deniz

Gupta

. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005;29:31–48.

36.

Milgrom

Fick

Jr.

. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:1966–73.

37.

FDA Alert. Information for Healthcare Professionals. Omalizumab. www.fda.gov/cder/drug/infopage/omalizumab/default.htm (accessed 2007 Mar 23).

38.

Lieberman

. Anaphylaxis and anaphylactoid reactions. In: Middleton

Reed

Ellis

Adkinson

Yunginger

Busse

, eds. Allergy: principles and practice. 5th ed. St. Louis, MO: Mosby-Year Book, Inc., 1998: 1079.

39.

Data on file. San Francisco: Genentech, Inc.

40.

Berger

Gupta

McAlary

Fowler-Taylor

. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003;91:182–8.

41.

The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (omalizumab) During Pregnancy (EXPECT). Identifier NCT00373061. www.clinicaltrials.gov/ct/show/NCT00373061?order=1 (accessed 2007 Mar 26).

42.

De Smet

Erickson

Kirking

. Self-reported adherence in patients with asthma. Ann Pharmacother 2006;40:414–20. Epub 28 Feb 2006. DOI 10.1345/aph.1G475

43.

Sherman

Patel

Hutson

Chesrown

Hendeles

. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Pharmacotherapy 2001;21:1464–7.

44.

Weinstein

. Should patients with persistent severe asthma be monitored for medication adherence? Ann Allergy Asthma Immunol 2005;94:251–7.

45.

Walley

Newell

Khan

. Directly observed therapy and treatment adherence (letter). Lancet 2000;356:1031–2.

46.

Hendeles

Khan

Massanari

Spencer

Shuster

Chesrown

. The effect of omalizumab on airway responsiveness to adenosine in asthma patients with poor adherence to inhaled steroids (abstract). Am J Respir Crit Care Med 2007;175: A58.

47.

Bousquet

Wenzel

Holgate

Lumry

Freeman

Fox

. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378–86.

48.

Bang

Plosker

. Spotlight on omalizumab in allergic asthma. Bio-Drugs 2004;18:415–8.

49.

Lowe

Jaffe

Martin

Brookman

Fox

. The effect of discontinuing omalizumab therapy on free IgE concentration (abstract). J Allergy Clin Immunol 2007;119(suppl):S6.

50.

Oba

Salzman

. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265–9.

51.

Miller

Reeves

. Lack of cost-effectiveness of omalizumab. J Allergy Clin Immunol 2005;115:429–30.

52.

Asche

Brixner

Oderda

. Has the cost-effectiveness of Xolair (omalizumab) been underestimated? J Allergy Clin Immunol 2005;115:1095–6.

53.

Rosenwasser

Nash

. Incorporating omalizumab into asthma treatment guidelines: Consensus Panel recommendations. Pharm Ther 2003;28:400–14.

54.

Marshall

Jr.

Sorkness

. IgE-blocking therapy for difficult-to-treat asthma: a brief review. Manag Care 2004;13:45–50.